Corporate venturing unit Trumpf Venture invested $4.5m to help the diabetes monitor developer close the round at $12.1m.

RSP Systems, a spinout of University of Southern Denmark, has extended its series B round to $12.1m following a $4.5m extension backed by Trumpf Venture.

The immuno-oncology therapy developer's investors include Pfizer and Gilead Sciences, both of which contributed to a $300m round in January.

The psychiatric and neurological disease drug developer has secured $25m in a series B round co-led by Pfizer Ventures.

The GSK-backed small molecule drug developer floated at the top of its range to raise just over $106m.

Cancer drug developer ViraTherapeutics has been acquired by Boehringer Ingelheim, three years after the corporate led its series A round.

Oncology diagnostics technology developer Epic Sciences, whose investors include Genomic Health, Pfizer and Roche, has now raised at least $135m in total.

The healthcare provider, which has become an increasingly active investor, has formed a corporate venturing unit called Cigna Ventures.

Ten businesses will receive $52,000 in grant funding for participating in a Francis Crick-operated accelerator for data science-powered biomedical interfaces.

University of Melbourne and Lockheed Martin have contributed to an additional $94.8m tranche for the Csiro Innovation Fund, bringing its total to $167m.